multiple sclerosis, fingolimod, adult, FTY720, inflammatory disease, demyelination, auto-inflammatory disease, relapsing-remitting MS, CFTY720D2406
Showing 1 - 25 of >10,000
Multiple Sclerosis Trial in Pavia (18F-florbetaben PET/CT)
Recruiting
- Multiple Sclerosis
- 18F-florbetaben PET/CT
-
Pavia, PV, ItalyICS Maugeri SpA SB IRCCS
Mar 23, 2023
Multiple Sclerosis, Relapsing-Remitting Trial in Chisinau (IMCY-0141, Placebo, Dimethyl Fumarate)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- IMCY-0141
- +2 more
-
Chisinau, Moldova, Republic ofRepublican Clinical Hospital, ARENSIA Exploratory Medicine
Jun 8, 2022
Multiple Sclerosis, Relapsing-Remitting, Caloric Restriction Trial in Pozzilli (Caloric restriction, Caloric restriction without
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Caloric Restriction
- Caloric restriction
- Caloric restriction without cow's milk and gluten
-
Pozzilli, IS, ItalyNeuromed - Istituto Neurologico Mediterraneo Pozzilli
Jul 26, 2022
Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)
Recruiting
- Relapsing Multiple Sclerosis (RMS)
- Fingolimod 0.5mg
-
Beijing, Beijing, China
- +12 more
Feb 3, 2022
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection Trial in Houston (Fingolimod, Placebo)
Enrolling by invitation
- Interstitial Fibrosis
- +6 more
- Fingolimod
- Placebo
-
Houston, TexasHouston Methodist Research Institute
Jan 23, 2023
Back Pain Trial (Pilates Exercise, Mckenzie Exercise)
Not yet recruiting
- Back Pain
- Pilates Exercise
- Mckenzie Exercise
- (no location specified)
Jun 1, 2023
Multiple Sclerosis Trial in Cairo (Blood sample collection)
Recruiting
- Multiple Sclerosis
- Blood sample collection
-
Cairo, EgyptNasser Institute for Research and Treatment
Feb 21, 2023
Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)
Terminated
- Relapsing Remitting Multiple Sclerosis
- Pleneva TM BGC20-0134
- Placebo
-
Gent, Belgium
- +34 more
Jun 2, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Early Aggressive Therapy or Traditional Therapy
-
Birmingham, Alabama
- +51 more
Jan 23, 2023
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic Trial in Winston-Salem (Fingolimod 0.5 mg, Placebo, Standard of
Recruiting
- Intracerebral Hemorrhage
- +4 more
- Fingolimod 0.5 mg
- +2 more
-
Winston-Salem, North CarolinaWake Forest University Health Sciences
Nov 28, 2022
Multiple Sclerosis Trial in Clermont-Ferrand (Methylprednisolone, Placebo, natalizumab (NTZ))
Recruiting
- Multiple Sclerosis
- Methylprednisolone
- +3 more
-
Clermont-Ferrand, FranceCHU Clermont-Ferrand
Jan 5, 2023
Multiple Sclerosis Trial (Randomized clinical trial.)
Not yet recruiting
- Multiple Sclerosis
- Randomized clinical trial.
- (no location specified)
Sep 26, 2022
Multiple Sclerosis Trial in Bratislava ("Tai-chi" - a special program for patients with multiple sclerosis - once a week
Completed
- Multiple Sclerosis
- "Tai-chi" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes
-
Bratislava, Slovak Republic, Slovakia2nd Department of Neurology, Faculty of Medicine COMENIUS UNIVER
Jul 21, 2022
Multiple Sclerosis Trial in Brussels (Visual Evoked Potential (VEP), Somatosensory evoked potential (SSEP), Transcranial
Recruiting
- Multiple Sclerosis
- Visual Evoked Potential (VEP)
- +5 more
-
Brussels, BelgiumCHU Brugmann
Jul 4, 2023
MS Trial in Giza (strengthening ex with BFR training, strengthening ex)
Recruiting
- MS
- strengthening ex with BFR training
- strengthening ex
-
Giza, EgyptFaculty of physical therapy
Nov 16, 2023
Multiple Sclerosis, Relapsing-Remitting Trial in Switzerland (serum Neurofilament Filament Light chain (sNfL) monitoring)
Not yet recruiting
- Multiple Sclerosis, Relapsing-Remitting
- serum Neurofilament Filament Light chain (sNfL) monitoring
-
Basel, Basel Stadt, Switzerland
- +7 more
Oct 17, 2023
Multiple Sclerosis, Relapsing-Remitting Trial in Porto Alegre (Cladribine 10 mg oral tablet)
Active, not recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Cladribine 10 mg oral tablet
-
Porto Alegre, RS, BrazilPontifical Catholic University of Rio Grande do Sul
Jun 5, 2023
Neurodegeneration in Multiple Sclerosis -Preclinical Study
Not yet recruiting
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- +2 more
- Peripheral blood withdrawal
-
Pozzilli, Isernia, Italy
- +2 more
Feb 15, 2022
Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Ocrelizumab, Ocrelizumab Placebo, Fingolimod)
Recruiting
- Relapsing-Remitting Multiple Sclerosis
- Ocrelizumab
- +3 more
-
La Jolla, California
- +66 more
Jan 27, 2023
Relapsing Multiple Sclerosis Trial in United States (Fingolimod)
Completed
- Relapsing Multiple Sclerosis
-
Birmingham, Alabama
- +65 more
Oct 6, 2021
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination Trial (Tysabri Injectable Product, Placebo)
Recruiting
- Multiple Sclerosis
- Clinically Isolated Syndrome of Demyelination
- Tysabri Injectable Product
- Placebo
-
London, United KingdomRoyal London Hospital
Jan 25, 2023
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Saint Louis (Cladribine)
Recruiting
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
-
Saint Louis, Missouri
- +4 more
Jan 4, 2023